Circumvent PCV G2 : 250ds



Shipping calculated at checkout

For use in healthy swine as an aid in the prevention of viremia, aid in the reduction of virus shedding and aid  in the reduction of lymphoid infection caused by PCV2.

ONE single 2-mL intramuscular dose at 3 weeks of age or older or Two lower-volume doses -initial 1ml intramuscualar dose as early as 3 days old followed by second dose of 1ml 3 weeks later.

The next generation of circovirus protection provides more options for a

stronger start and more profitable finish. The ONLY PCV2 vaccine that’s approved for use in pigs as early as 3 days of age (two-dose option)  

Pigs are easiest to pick up by trusted, capable handlers 

Pigs are less likely to be stressed because they are still with their mothers 

Choose between two convenient options



With both options, pigs get off to a stronger start because they are

ready to face PCV2 before leaving farrowing. Same superior efficacy, now with industry-leading 5-month duration of immunity 4 weeks longer than the competition

Aids in the prevention of PCV2 viremia, which is the initial step in the

development of PCV2 disease It’s more effective to control the disease early on so damage caused by infection is limited or essentially eliminated


Merck Animal Health is the only company to bring a PCV2 vaccine to

market using a PCV2 and porcine reproductive and respiratory syndrome 

(PRRS) co-infection challenge model

Helps predict ability of vaccine to perform in real-world conditions 

 Microsol Diluvac Forte® adjuvant provides optimal immune response


Merck Animal Health is offering the first porcine circovirus Type 2 (PCV2) vaccine, Circumvent PCV G2 for use in pigs as early as three days of age. The new vaccine offers convenient one- or two-dose administration options with five-month duration of immunity (DOI), which is at least 25 percent longer than any other PCV2 vaccine on the market

"Vaccines with longer DOI can provide better protection and potentially reduce mortality just prior to marketing, where the loss of a pig approaches its market value," says Derald Holtkamp, DVM, associate professor, Iowa State University College of Veterinary Medicine. "In a barn of 1,000 pigs, if just one 270-pound pig is saved, and carcass prices are at $1 per pound, the benefit is more than $200, or $0.20 per pig."

Merck Animal Health is focused on providing new products that get pigs off to a healthy, stronger start for a more profitable finish, as well as on responding to the changing needs of its customers.

"Whether your operation uses a one-dose vaccine protocol or you choose to vaccinate with two doses, Circumvent PCV G2 offers you convenience and the same superior efficacy you have come to expect from our Circumvent line of vaccines," says Brad Thacker, Merck Animal Health senior technical services veterinarian. "We are pleased that we can now offer our customers options that make their operations even more efficient and productive, and excited that this new vaccine is just the beginning of what we will be able to offer the industry in terms of PCV2 protection."

Circumvent PCV G2 aids in the prevention of PCV2 viremia, which helps stop infection early in the disease process before tissue damage can occur. This in turn helps reduce the risk of co-infection from porcine reproductive and respiratory syndrome virus (PRRSv), Mycoplasma hyopneumoniae and swine influenza virus (SIV) because the immune system is not compromised. This vaccine also aids in the reduction of virus shedding and lymphoid infection.